T
Tea Zeppola
Researcher at Università Campus Bio-Medico
Publications - 14
Citations - 774
Tea Zeppola is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 9, co-authored 14 publications receiving 450 citations.
Papers
More filters
Journal ArticleDOI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini,Melissa Bersanelli,Sebastiano Buti,Katia Cannita,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Maria Michiara,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Daniela Iacono,Alain Gelibter,Mario Occhipinti,Alessandro Parisi,Giampiero Porzio,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella,Clara Natoli +44 more
TL;DR: Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs and BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.
Journal ArticleDOI
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini,Sebastiano Buti,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Melissa Bersanelli,Maria Michiara,Antonino Grassadonia,Davide Brocco,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Roberto Sabbatini,Sergio Bracarda,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Daniela Iacono,Maria Rita Migliorino,Antonio Rossi,Giampiero Porzio,Katia Cannita,Valeria Ciciarelli,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella +44 more
TL;DR: The finding of a greater incidence of irAEs among female patients ranks among the "hot topics" in gender-related differences in immuno-oncology.
Journal ArticleDOI
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini,Rita Chiari,Biagio Ricciuti,Giulio Metro,Fabiana Perrone,Marcello Tiseo,Melissa Bersanelli,Paola Bordi,Daniele Santini,Raffaele Giusti,Antonino Grassadonia,Pietro Di Marino,N. Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Daniela Iacono,Maria Rita Migliorino,Giampiero Porzio,Katia Cannita,Corrado Ficorella,Sebastiano Buti +34 more
TL;DR: It is confirmed that irAEs are concordantly related to higher ORR, longer PFS, and longer OS with anti-PD-1 immunotherapy in patients with NSCLC.
Journal ArticleDOI
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Emanuela Dell'Aquila,Chiara Cremolini,Tea Zeppola,Sara Lonardi,Francesca Bergamo,Gianluca Masi,Marco Stellato,Federica Marmorino,Marta Schirripa,Federica Urbano,Monica Ronzoni,Gianluca Tomasello,A. Zaniboni,Patrizia Racca,Angela Buonadonna,Giacomo Allegrini,E. Fea,S. Di Donato,Silvana Chiara,G. Tonini,Daniela Tomcikova,Luigi Boni,Alfredo Falcone,Daniele Santini +23 more
TL;DR: The prognostic role of NLR was confirmed in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR, and the advantage of the triplet is independent ofNLR at baseline.
Journal ArticleDOI
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Alessio Cortellini,Melissa Bersanelli,Daniele Santini,Sebastiano Buti,Marcello Tiseo,Katia Cannita,Fabiana Perrone,Raffaele Giusti,Michele De Tursi,Federica Zoratto,Riccardo Marconcini,Marco Russano,Tea Zeppola,Cecilia Anesi,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Alain Gelibter,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Marianna Tudini,Rosa Rita Silva,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Maria Rita Migliorino,Domenico Mallardo,Vito Vanella,Claudia Mosillo,Sergio Bracarda,Silvia Rinaldi,Rossana Berardi,Clara Natoli,Corrado Ficorella,Giampiero Porzio,Paolo A. Ascierto +37 more
TL;DR: Considering the previously evidenced association between higher BMI and better outcome, the current finding about the relationship between BMI and irAEs occurrence can contribute to consideration of these findings as the upside of the downside, which underlies an 'immunogenic phenotype'.